M.D., Medical Director, Admera Health
Biography
Dr. Ruben Bonilla-Guerrero's interests include clinical pharmacology and genetics with a focus on pharmacogenomics. At Admera Health he is responsible for the clinical content of genomic-based assays and leading the medical affairs team. Dr. Ruben Bonilla-Guerrero obtained his medical degree from the Universidad Veracruzana in Mexico. From there, he moved to the Mayo Clinic in Rochester Minnesota where he completed his training in Clinical Pharmacology and Clinical Biochemical Genetics, spending 14 years focusing on research and clinical laboratory medicine. Prior to joining Admera Health, Dr. Bonilla-Guerrero spent over nine years at Quest Diagnostics in both Laboratory Director and Medical Directors roles. Dr. Bonilla-Guerrero is board certified in Clinical Biochemical Genetics by the American Board of Clinical Pharmacology and American Board of Medical Genetics (ABMG) and in Molecular Biology by the American Society of Clinical Pathology (ASCP).
Clinical Dx Showcase:
Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focusing on Advancing Precision Medicine Beyond Diagnostics. Its flagship product is PGxOne™ Plus test, a comprehensive pharmacogenomics (PGx) test.
Pharmacogenomics: An Introduction To Proper Clinical Adoption
The use of Pharmacogenomics to help predict drug response is becoming more widespread. However, it is not always being used in a way that will maximize patient outcomes the way Admera Health’s PGxOne™ Plus does.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
